

SEQUENCE LISTING

<110> Agency for Science, Technology and Research

<120> ANTI-CTLA-4 ANTIBODIES

<130> RIC/FP7253289

<140> 10201603721T

<141> 2016-05-10

<160> 14

<170> PatentIn version 3.5

<210> 1

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone light chain variable domain

<400> 1

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Thr Gln Gly Ile Ser Ser Trp
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Thr Leu Pro Leu
85 90 95

Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105

<210> 2

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 gl clone light chain variable domain

<400> 2

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Thr Gln Gly Ile Ser Ser Trp
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Thr Leu Pro Leu
85 90 95

Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105

<210> 3

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone heavy chain variable domain

<400> 3

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Thr Val Ser Ser Asn
20 25 30

Thr Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Asp Tyr Gly
50 55 60

Leu Ser Val Lys Ser Arg Met Thr Ile Asn Ala Asp Thr Ser Lys Asn
65 70 75 80

Gln Val Ser Leu His Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
85 90 95

Tyr Tyr Cys Ala Arg Glu Gly Ser Gly Gly Thr Leu Ile Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 4

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 gl clone heavy chain variable domain

<400> 4

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
20 25 30

Thr Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
35 40 45

Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Asp Tyr Gly
50 55 60

Leu Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
65 70 75 80

Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
85 90 95

Tyr Tyr Cys Ala Arg Glu Gly Ser Gly Gly Thr Leu Ile Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone light chain variable domain
LC-CDR1

<400> 5

Arg Ala Thr Gln Gly Ile Ser Ser Trp Leu Ala
1 5 10

<210> 6

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone light chain variable domain
LC-CDR2

<400> 6

Ala Ala Ser Ser Leu Gln Ser

1 5

<210> 7

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone light chain variable domain
LC-CDR3

<400> 7

Gln Gln Ala Asn Thr Leu Pro Leu Phe Thr

1 5 10

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone heavy chain variable domain
LC-CDR1

<400> 8

Ser Asn Thr Ala Ala Trp Asn

1 5

<210> 9

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone heavy chain variable domain
LC-CDR2

<400> 9

Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Asp Tyr Gly Leu Ser Val
1 5 10 15

Lys Ser

<210> 10

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone heavy chain variable domain
LC-CDR3

<400> 10

Glu Gly Ser Gly Gly Thr Leu Ile Tyr
1 5

<210> 11

<211> 324

<212> DNA

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone light chain variable domain

<400> 11

gacatccagt tgaccagtc tccatcttct gtgtctgcat ctgtgggaga cagagtcacc 60

atcacttgct gggcgactca ggggtataagc agctggtag cctggtatca gcagaaacca 120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatcc 180

aggttcagcg gcagtggtc tgggacagag ttactctca ctatcagcag cctgcagcct 240

gaagatttg caacttacta ttgtcaacag gctaatactc tccccttatt cacttcggc 300

cctgggacca aagtggatat caaa

324

<210> 12

<211> 324

<212> DNA

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 gl clone light chain variable domain

<400> 12

gacatccaga tgaccagtc tccatcttct gtgtctgcat ctgtgggaga cagagtcacc 60

atcacttgtc gggcgactca gggataagc agctggtag cctggatatca gcagaaacca 120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatcc 180

aggttcagcg gcagtggctc tgggacagat ttactctca ctatcagcag cctgcagcct 240

gaagattttg caacttacta ttgtcaacag gctaatactc tccccttatt cactttcggc 300

cctgggacca aagtggatat caaa

324

<210> 13

<211> 363

<212> DNA

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 clone heavy chain variable domain

<400> 13

caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgagac cctctcactc 60

acctgcgcca tctccgggga cactgtctct agcaacactg ctgcttgga ttggatcagg 120

cagtccccct cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggat 180

agtgactatg gactatctgt gaaaagtcgg atgaccatca atgcagacac atccaagaac 240

caggctctcc tacacctgaa ctctgtaact cccgaagaca cggctgtata ttactgtgca 300

agagagggca gtggcggaac ttgatctac tggggccagg gaaccctggt caccgtctca 360

agc

363

<210> 14

<211> 363

<212> DNA

<213> Artificial Sequence

<220>

<223> anti-CTLA-4 antibody 2C8 gl clone heavy chain variable domain

<400> 14

caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgagac cctctcactc 60

acctgcgcca tctccgggga cagtgtctct agcaacactg ctgcttgga ttggatcagg 120

cagtccccct cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggat 180

agtgactatg gactatctgt gaaaagtcgg ataaccatca atccagacac atccaagaac 240

cagttctccc tacagctgaa ctctgtaact cccgaagaca cggctgtata ttactgtgca 300

agagagggca gtggcggaac ttgatctac tggggccagg gaaccctggt caccgtctca 360

agc

363